MTOR and cancer: Although mTOR plays important roles in regulating cancer cell growth, metabolism and protein synthesis, the allosteric mTOR inhibitor rapamycin (sirolimus) fails to be approved as an anti-cancer agent due to its immunosuppresive effects [83].